Key clinical point: An investigational RSV monoclonal antibody was safe and effective for cutting infection rates during 150 days after a single dose.
Major finding: The incidence of medically attended lower respiratory tract RSV infection was 2.6% with nirsevimab and 9.5% with placebo.
Study details: A multicenter, placebo-controlled study with 969 infants treated with nirsevimab and 484 treated with placebo.
Disclosures: The study was funded by AstraZeneca, the company developing nirsevimab. Dr. Griffin is an employee of and shareholder in AstraZeneca.
ClinicalTrials.gov identifier: NCT02878330.